ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia

Bookmark and Share
Published: 15 Jun 2020
Views: 470
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

Prof Constantine Tam talks to ecancer in an online interview for the ASCO virtual meeting 2020 about the ASPEN study.

Prof Tam outlines the study design which compares two BTK (bruton tyrosine kinase) inhibitors for the first time.

He discusses the results, which despite not reaching the primary endpoint, showed promise for zanubrutinib when it came to toxicities.